M. Wolf

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf et al. · OncoImmunology · 2018 · 170 citations · Full text

Immunology, Pharmacotherapy, Immunotherapeutics +19

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland et al. · Journal of Thoracic Oncology · 2021 · 147 citations · Full text

Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival

M. Wolf, Rolf Holle, K. Hans et al. · British Journal of Cancer · 1991 · 146 citations · Full text

Prognostic Factors, Cancer Risk, Medicine +6

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study

Georg Richtig, Christoph Höeller, M. Wolf et al. · PLoS ONE · 2018 · 118 citations · Full text

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

Franck Morschhauser, John F. Seymour, Hanneke C. Kluin‐Nelemans et al. · Annals of Oncology · 2007 · 97 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +6